Quantcast

Latest Ranibizumab Stories

2010-06-15 15:00:00

INCLINE VILLAGE, Nev., June 15 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the second quarter ended June 30, 2010 of approximately $120 million, as compared with actual results of $125.9 million for the second quarter of 2009. Included in second quarter 2010 guidance is $1.5 million earned on Eurodollar foreign currency hedging contracts that the Company initiated in January 2010. Included in actual results for the second quarter...

2010-06-11 13:35:48

An inexpensive, but unlicensed drug to help prevent severe sight loss in older people has been shown to be safe and effective, finds a study published on bmj.com today. Bevacizumab (Avastin) is licensed as a treatment for bowel cancer, but it is widely used "off label" as a considerably cheaper alternative to the approved drug ranibizumab (Lucentis) to prevent wet age related macular degeneration (AMD) and several large trials comparing the two drugs are now underway. Although ranibizumab was...

2010-05-03 07:28:12

Highlights of May 2010 Ophthalmology The May issue of Ophthalmology, the journal of the American Academy of Ophthalmology, includes a surprising, first report on increasing rates of age-related macular degeneration (AMD) among Asians, and describes an innovative "bypass" laser surgery that may help many people with central retinal vein occlusion (CRVO) avoid serious vision loss. Are Asians as Vulnerable to AMD as Caucasians? A major review by Tien Yi Wong, MD, MPH, PhD, and Singapore Eye...

2010-04-27 14:22:59

Ranibizumab injections plus laser therapy results in dramatic visual improvement Researchers have shown that ranibizumab (Lucentis) eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the retina. Laser treatment alone has been the standard care for the past 25 years. But nearly 50 percent of patients who received this new treatment experienced substantial visual improvement after one year, compared...

7610df092f0784cd58ed11ebbd3995bf1
2010-04-27 12:42:14

Diabetic retinopathy clinical research network study finds new treatment more effective A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration (AMD). Treating diabetic macular edema (DME) with ranibizumab (Lucentis) eye injections, plus laser treatment if needed, appears to result in better vision than laser treatment...

2010-04-26 07:00:00

PRINCETON, N.J., April 26 /PRNewswire/ -- Ophthotech Corp. ("Ophthotech"), a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD). The Phase II trial will assess the efficacy...

2010-03-08 16:57:20

Use of medications injected directly into the eye appears to be an increasingly common treatment for age-related macular degeneration in one region of Canada, but only a small proportion of ophthalmologists perform the procedure, according to a report in the March issue of Archives of Ophthalmology, one of the JAMA/Archives journals. Age-related macular degeneration is the leading cause of blindness in Western nations, according to background information in the article. The development of...

2010-02-18 06:00:00

TARRYTOWN, N.Y. and LEVERKUSEN, Germany, Feb. 18 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare AG today announced that VEGF Trap-Eye showed positive results in a Phase 2 study in patients with diabetic macular edema (DME). The primary endpoint of the study, a statistically significant improvement in visual acuity over 24 weeks compared to the standard of care in DME, macular laser therapy, was met. Visual acuity improvement was measured...

2010-02-16 07:00:00

WALTHAM, Mass., Feb. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that both Genentech/Novartis Ophthalmics' Lucentis and Regeneron/Bayer's aflibercept will earn Decision Resources' proprietary clinical gold standard status for wet age-related macular degeneration in 2013 and 2018. A unique future gold standard cannot be identified because neither thought-leader opinion nor available clinical...

2010-02-01 13:13:43

Ophthalmology February highlights This month's Ophthalmology, the journal of the American Academy of Ophthalmology, includes results from a large Kaiser Permanente study of age-related macular degeneration (AMD) treatments, the first global report on retinal vein occlusion, and new recommendations to help elders with vision loss avoid falls. Kaiser Study Compares Effectiveness of Two AMD Drugs A Kaiser Permanente Southern California study compared two very similar medications"“...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related